Concomitant tumor resistance
- PMID: 22634498
- DOI: 10.1016/j.canlet.2012.05.021
Concomitant tumor resistance
Abstract
Concomitant tumor resistance (CR) is a phenomenon in which a tumor-bearing host is resistant to the growth of secondary tumor implants. This phenomenon has been described in human and animal systems and it can be generated by both immunogenic and non-immunogenic tumors. The relevance of CR to the mechanisms of metastases control has been highlighted by numerous observations showing that the removal of human and murine tumors may be followed by an abrupt increase in metastatic growth, suggesting that a primary tumor may exert a controlling action on its metastases which could be considered as secondary tumor implants developed spontaneously during the primary tumor growth. A more profound understanding of the different mechanisms claimed to be associated with the phenomenon of CR could contribute to develop new and more harmless means to manage malignant diseases, especially by limiting the development of metastases that arise after resection of primary tumors or after other stressors that may promote the escape of metastases from dormancy.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Concomitant tumor resistance: the role of tyrosine isomers in the mechanisms of metastases control.Cancer Res. 2012 Mar 1;72(5):1043-50. doi: 10.1158/0008-5472.CAN-11-2964. Epub 2012 Feb 7. Cancer Res. 2012. PMID: 22315349 Review.
-
Tyrosine isomers mediate the classical phenomenon of concomitant tumor resistance.Cancer Res. 2011 Nov 15;71(22):7113-24. doi: 10.1158/0008-5472.CAN-11-0581. Cancer Res. 2011. PMID: 22084446
-
Modeling growth kinetics and statistical distribution of oligometastases.Semin Radiat Oncol. 2006 Apr;16(2):111-9. doi: 10.1016/j.semradonc.2005.12.006. Semin Radiat Oncol. 2006. PMID: 16564446 Review.
-
Meta-tyrosine. A powerful anti-metastatic factor with undetectable toxic-side effects.Medicina (B Aires). 2015;75(1):1-5. Medicina (B Aires). 2015. PMID: 25637892
-
Effects of concomitant and sinecomitant immunity on postsurgical metastasis in mice.Cancer Res. 1986 Dec;46(12 Pt 1):6111-5. Cancer Res. 1986. PMID: 3779631
Cited by
-
Investigating the Impact of a Primary Tumor on Metastasis and Dormancy Using MRI: New Insights into the Mechanism of Concomitant Tumor Resistance.Tomography. 2016 Jun;2(2):79-84. doi: 10.18383/j.tom.2016.00151. Tomography. 2016. PMID: 30042958 Free PMC article.
-
A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin.J Ovarian Res. 2021 Nov 16;14(1):157. doi: 10.1186/s13048-021-00895-w. J Ovarian Res. 2021. PMID: 34784944 Free PMC article.
-
Multimodality cellular and molecular imaging of concomitant tumour enhancement in a syngeneic mouse model of breast cancer metastasis.Sci Rep. 2018 Jun 12;8(1):8930. doi: 10.1038/s41598-018-27208-4. Sci Rep. 2018. PMID: 29895974 Free PMC article.
-
Hypothesis: Cancer Hormesis and Its Potential for Cancer Therapeutics.Life (Basel). 2024 Mar 18;14(3):401. doi: 10.3390/life14030401. Life (Basel). 2024. PMID: 38541725 Free PMC article.
-
Surgery for Cancer: A Trigger for Metastases.Cancer Res. 2017 Apr 1;77(7):1548-1552. doi: 10.1158/0008-5472.CAN-16-1536. Epub 2017 Mar 22. Cancer Res. 2017. PMID: 28330928 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources